REGN: Regeneron Pharmaceuticals Inc. Stocks News on February 22, 2025

2 Healthcare Stocks with Big Upside and 1 to Skip

REGN

StockStory

a day ago

2 Healthcare Stocks with Big Upside and 1 to Skip

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

REGN

Investopedia

4 days ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

This Company Just Initiated a Quarterly Dividend: Time to Buy?

REGN

Motley Fool

4 days ago

This Company Just Initiated a Quarterly Dividend: Time to Buy?

REGN

Zacks

4 days ago

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

REGN

Pharmaceutical Technology

4 days ago

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

REGN

GlobeNewswire

4 days ago

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

REGN

Zacks

8 days ago

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

REGN

Simply Wall St.

9 days ago

Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders

Regeneron Announces Investor Conference Presentations

REGN

GlobeNewswire

11 days ago

Regeneron Announces Investor Conference Presentations

REGN

MT Newswires

11 days ago

Regeneron Pharmaceuticals' Blood Cancer Drug Application Accepted by FDA

$Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma$

REGN

GlobeNewswire

11 days ago

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

REGN

MT Newswires

11 days ago

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,200, Maintains Buy Rating

Regeneron’s macular oedema therapy shows promise in Phase III trial

REGN

Clinical Trials Arena

12 days ago

Regeneron’s macular oedema therapy shows promise in Phase III trial

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

REGN

Motley Fool

12 days ago

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

REGN

Simply Wall St.

13 days ago

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

REGN

StockStory

13 days ago

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

REGN

GlobeNewswire

14 days ago

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

REGN

GlobeNewswire

14 days ago

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

REGN

Morningstar Research

15 days ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

REGN

Zacks

17 days ago

Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval

REGN

MT Newswires

17 days ago

Bernstein Adjusts Regeneron Pharmaceuticals Price Target to $1,010 From $1,000

REGN

MT Newswires

17 days ago

Baird Adjusts Regeneron Pharmaceuticals Price Target to $759 From $940

REGN

MT Newswires

17 days ago

Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,019 From $1,182

REGN

MT Newswires

17 days ago

Morgan Stanley Adjusts Regeneron Pharmaceuticals Price Target to $1,150 From $1,185

REGN

MT Newswires

17 days ago

UBS Adjusts Price Target on Regeneron Pharmaceuticals to $768 From $738, Maintains Neutral Rating

REGN

MT Newswires

17 days ago

RBC Trims Price Target on Regeneron Pharmaceuticals to $1,045 From $1,059, Keeps Outperform Rating

REGN

MT Newswires

17 days ago

Leerink Upgrades Regeneron Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $834 From $762

Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

REGN

Simply Wall St.

17 days ago

Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

REGN

Zacks

17 days ago

Company News for Feb 5, 2025

REGN

GuruFocus.com

17 days ago

Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

REGN

Thomson Reuters StreetEvents

17 days ago

Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

REGN

Motley Fool

18 days ago

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

REGN

Insider Monkey

18 days ago

Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?

REGN

MT Newswires

18 days ago

Sector Update: Health Care Stocks Mixed Premarket Tuesday

Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations

REGN

Investor's Business Daily

18 days ago

Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations

Regeneron beats quarterly estimates on eczema drug demand; launches dividend program

REGN

Reuters

18 days ago

Regeneron beats quarterly estimates on eczema drug demand; launches dividend program

REGN

Zacks

18 days ago

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

REGN

Associated Press Finance

18 days ago

Regeneron: Q4 Earnings Snapshot

REGN

MT Newswires

18 days ago

Regeneron Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise -- Shares Up Pre-Bell

REGN

StockStory

18 days ago

Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars

REGN

Insider Monkey

20 days ago

Why Are Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?

Regeneron to Report Q4 Earnings: Is a Beat in the Cards?

REGN

Zacks

22 days ago

Regeneron to Report Q4 Earnings: Is a Beat in the Cards?

REGN

MT Newswires

22 days ago

Bernstein Adjusts Regeneron Pharmaceuticals Price Target to $1,000 From $1,070

REGN

Zacks

22 days ago

Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

REGN

MT Newswires

23 days ago

Wolfe Research Cuts Regeneron Pharmaceuticals Price Target to $1,000 From $1,150

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

REGN

Zacks

23 days ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback

REGN

The Wall Street Journal

23 days ago

Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback

Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline

REGN

Zacks

24 days ago

Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline

REGN

MT Newswires

24 days ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $903 From $950, Keeps Outperform Rating

REGN

MT Newswires

24 days ago

TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,030 From $1,230, Keeps Buy Rating

REGN

Zacks

25 days ago

Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline

REGN

Zacks

25 days ago

Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options

REGN

Insider Monkey

25 days ago

Is Regeneron Pharmaceuticals (REGN) Among the Best Depressed Stocks to Invest in Now?

REGN

MT Newswires

25 days ago

Leerink Partners Adjusts Regeneron Pharmaceuticals Price Target to $762 From $880, Maintains Market Perform Rating

REGN

MT Newswires

25 days ago

Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $795, Maintains Neutral Rating

Drugmakers Show Restraint on Price Increases in New Trump Era

REGN

The Wall Street Journal

25 days ago

Drugmakers Show Restraint on Price Increases in New Trump Era

REGN

Insider Monkey

a month ago

Is Regeneron Pharmaceuticals (REGN) the Best Stock to Buy and Hold for 2025?

REGN

MT Newswires

a month ago

Piper Sandler Cuts Price Target on Regeneron Pharmaceuticals to $1,013 From $1,195, Maintains Overweight Rating

REGN

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,182 From $1,185, Maintains Buy Rating

REGN

Insider Monkey

a month ago

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?

America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

REGN

PR Newswire

a month ago

America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

REGN

MT Newswires

a month ago

RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,059 From $1,184, Maintains Outperform Rating

REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES

REGN

CNW Group

a month ago

REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES

REGN

Insider Monkey

a month ago

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

REGN

Zacks

a month ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

REGN

Zacks

a month ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

REGN

Fortune

a month ago

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

REGN

Zacks

a month ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

REGN

Investing.com

a month ago

UBS cuts rating on Regeneron stock amid Eylea uncertainty

REGN

MT Newswires

a month ago

UBS Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Cuts Price Target to $738 From $1,130

REGN

Insider Monkey

a month ago

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’

REGN

Simply Wall St.

a month ago

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Regeneron Reports Eylea Sales, Provides Other Pipeline Updates

REGN

Zacks

a month ago

Regeneron Reports Eylea Sales, Provides Other Pipeline Updates

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

REGN

Investor's Business Daily

a month ago

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

REGN

MT Newswires

a month ago

Jefferies Adjusts Regeneron Pharmaceuticals Price Target to $1,120 From $1,200

Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database

REGN

Medical Device Network

a month ago

Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database

REGN

MT Newswires

a month ago

Citigroup Cuts Regeneron Pharmaceuticals' Price Target to $795 From $895

Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint

REGN

Investor's Business Daily

a month ago

Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint

Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?

REGN

Zacks

a month ago

Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals Invests $119.5 Million in Truveta to Launch Genome Project

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals' Trial Shows Adjuvant Libtayo Improved Disease-Free Survival After Surgery in CSCC Patients

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

REGN

GlobeNewswire

a month ago

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

REGN

GlobeNewswire

a month ago

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

Truveta sells stakes to Regeneron, Illumina in deal to build genetic database

REGN

Reuters

a month ago

Truveta sells stakes to Regeneron, Illumina in deal to build genetic database

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

REGN

GlobeNewswire

a month ago

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

REGN

Zacks

a month ago

Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again

REGN

MT Newswires

a month ago

Wells Fargo Cuts Price Target on Regeneron Pharmaceuticals to $900 From $1,050, Maintains Overweight Rating

REGN

MT Newswires

a month ago

Oppenheimer Adjusts Regeneron Pharmaceuticals' Price Target to $950 From $1,000, Keeps Outperform Rating

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

REGN

Zacks

a month ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

REGN

MT Newswires

a month ago

Truist Trims Price Target on Regeneron Pharmaceuticals to $1,004 From $1,126, Keeps Buy Rating

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

REGN

GlobeNewswire

a month ago

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

REGN

MT Newswires

a month ago

RBC Trims Price Target on Regeneron Pharmaceuticals to $1,184 From $1,215, Keeps Outperform Rating

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder

REGN

Pharmaceutical Technology

2 months ago

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder

1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street

REGN

Motley Fool

2 months ago

1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street

REGN

Insider Monkey

2 months ago

Jim Cramer’s Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the Future

REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

REGN

Zacks

2 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

REGN

MT Newswires

2 months ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating

REGN

MT Newswires

2 months ago

Regeneron Says Investigational Antibodies Show Antithrombotic Effects in Phase 2 Trial

Regeneron says study data support big bet on new blood thinners

REGN

BioPharma Dive

2 months ago

Latest Regeneron Pharmaceuticals Inc. (REGN) News on February 22, 2025

Share on Social Networks: